[go: up one dir, main page]

PE20181299A1 - Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos - Google Patents

Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos

Info

Publication number
PE20181299A1
PE20181299A1 PE2018000633A PE2018000633A PE20181299A1 PE 20181299 A1 PE20181299 A1 PE 20181299A1 PE 2018000633 A PE2018000633 A PE 2018000633A PE 2018000633 A PE2018000633 A PE 2018000633A PE 20181299 A1 PE20181299 A1 PE 20181299A1
Authority
PE
Peru
Prior art keywords
deleted
alanine
serine
acid
glutamine
Prior art date
Application number
PE2018000633A
Other languages
English (en)
Inventor
Sung Youb Jung
Myung Hyun Jang
Ling Ai Shen
Young Kyung Park
Young Jin Park
Se Chang Kwon
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47296599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20181299(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of PE20181299A1 publication Critical patent/PE20181299A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Referido a un peptido que comprende la siguiente secuencia aminoacidica: R1-X1-X2-GTFTSD-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-X22-X23-X24-R2, en donde: R1 es histidina, desaminohistidilo, dimetilhistidilo (N-dimetilhistidilo), entre otros; X1 es Aib (acido aminoisobutirico), d-alanina, glicina, Sar (N-metilglicina), serina o d-serina; X2 es acido glutamico o glutamina; X3 es leucina o tirosina; X4 es serina o alanina; X5 es lisina o arginina; X6 es glutamina o tirosina; X7 es leucina o metionina; X8 es acido aspartico o acido glutamico; X9 es acido glutamico, serina, acido alfa-metilglutamico o esta suprimido; X10 es glutamina, acido glutamico, lisina, arginina, serina o esta suprimido; X11 es alanina, arginina, valina o esta suprimido; X12 es alanina, arginina, serina, valina o esta suprimido; X13 es lisina, glutamina, arginina, acido alfa-metilglutamico o esta suprimido; X14 es acido aspartico, acido glutamico, leucina o esta suprimido; X15 es fenilalanina o esta suprimido; X16 es isoleucina, valina o esta suprimido; X17 es alanina, cisteina, acido glutamico, lisina, glutamina, acido alfa-metilglutamico o esta suprimido; X18 es triptofano o esta suprimido; X19 es alanina, isoleucina, leucina, serina, valina o esta suprimido; X20 es alanina, lisina, metionina, glutamina, arginina o esta suprimido; X21 es asparagina o esta suprimido; X22 es alanina, glicina, treonina o esta suprimido; X23 es cisteina, lisina o esta suprimido; X24 es un peptido que tiene de 2 a 10 aminoacidos consistentes en combinaciones d alanina, glicina y serina, o esta suprimido; y R2 es KRNRNNIA (SEQ ID NO: 32), GPSSGAPPPS (SEQ ID NO.33), entre otros. Este peptido es un derivado de oxintomodulina capaz de activar el receptor de Peptido similar al glucagon tipo 1 (CLP-1) y el receptor de glucagon; mejor que la oxintomodulina nativa, ya que reduce la ingesta de alimento, suprime el vaciado gastrico y facilita la lipolisis sin efectos secundarios reducidos, y muestra tambien excelentes efectos activadores de receptor; por lo tanto, puede usarse en el tratamiento de la obesidad con seguridad y eficacia. Tambien se refiere a una composicion para la prevencion o el tratamiento de la obesidad que comprende el peptido como un ingrediente activo.
PE2018000633A 2011-06-10 2012-06-07 Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos PE20181299A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20110056472 2011-06-10

Publications (1)

Publication Number Publication Date
PE20181299A1 true PE20181299A1 (es) 2018-08-09

Family

ID=47296599

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2018000633A PE20181299A1 (es) 2011-06-10 2012-06-07 Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos
PE2013002789A PE20140765A1 (es) 2011-06-10 2012-06-07 Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos
PE2023001927A PE20240686A1 (es) 2011-06-10 2012-06-07 Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1)

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2013002789A PE20140765A1 (es) 2011-06-10 2012-06-07 Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos
PE2023001927A PE20240686A1 (es) 2011-06-10 2012-06-07 Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1)

Country Status (32)

Country Link
US (4) US9527898B2 (es)
EP (3) EP3434687B1 (es)
JP (5) JP6014127B2 (es)
KR (2) KR101502299B1 (es)
CN (1) CN103732618B (es)
AR (1) AR086866A1 (es)
AU (4) AU2012267398B2 (es)
BR (2) BR112013031794B1 (es)
CA (2) CA3064214C (es)
CL (1) CL2013003547A1 (es)
CY (1) CY1120781T1 (es)
DK (3) DK3878859T5 (es)
ES (3) ES2692187T3 (es)
HR (1) HRP20181591T1 (es)
HU (1) HUE040307T2 (es)
IL (3) IL245557B (es)
LT (1) LT2718318T (es)
MX (3) MX391293B (es)
MY (1) MY169309A (es)
PE (3) PE20181299A1 (es)
PH (2) PH12013502518A1 (es)
PL (1) PL2718318T3 (es)
PT (1) PT2718318T (es)
RS (1) RS57711B1 (es)
RU (2) RU2739209C2 (es)
SG (2) SG10201604564XA (es)
SI (1) SI2718318T1 (es)
SM (1) SMT201800649T1 (es)
TW (2) TWI619724B (es)
UA (2) UA126465C2 (es)
WO (1) WO2012169798A2 (es)
ZA (1) ZA201309054B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
DK3878859T5 (da) * 2011-06-10 2024-06-10 Hanmi Science Co Ltd Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende disse
SI2721062T1 (sl) 2011-06-17 2019-03-29 Hanmi Science Co., Ltd. Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega
AR088161A1 (es) 2011-09-23 2014-05-14 Novo Nordisk As Analogos de glucagon
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
MY168536A (en) 2012-11-06 2018-11-12 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin fc region
MX2015008114A (es) 2012-12-21 2015-11-06 Sanofi Sa Derivados de exendina-4.
SI2986313T1 (sl) 2013-04-18 2019-09-30 Novo Nordisk A/S Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo
AR096890A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
AR098615A1 (es) * 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
AR098614A1 (es) * 2013-12-18 2016-06-01 Lilly Co Eli Compuesto para el tratamiento de hipoglicemia severa
CR20160376A (es) 2014-01-20 2016-10-07 Hanmi Pharm Ind Co Ltd Insulina de acción prolongada y uso de la misma
MX387560B (es) 2014-03-31 2025-03-18 Hanmi Pharmaceutical Co Ltd Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
KR20150140177A (ko) 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
KR102418477B1 (ko) * 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
KR102291020B1 (ko) * 2014-12-30 2021-08-20 한미약품 주식회사 안정성이 증가된 글루카곤 유도체
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
DK3322437T5 (da) * 2015-06-30 2024-10-07 Hanmi Pharmaceutical Co Ltd Glukagonderivat og en sammensætning omfattende et langtidsvirkende konjugat af samme
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
PE20250556A1 (es) 2015-12-31 2025-02-24 Hanmi Pharmaceutical Co Ltd Agonista triple de receptores de glucagon/glp-1/gip
CN109310743A (zh) * 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
CA3029518A1 (en) * 2016-06-29 2018-01-04 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof
KR102698929B1 (ko) 2016-09-23 2024-08-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도
WO2018105988A1 (ko) 2016-12-05 2018-06-14 한미약품 주식회사 면역반응이 약화된 결합체
CN108299554B (zh) * 2017-01-13 2021-05-25 博瑞生物医药（苏州）股份有限公司 胃泌酸调节素类似物
US20200230250A1 (en) 2017-02-03 2020-07-23 Hanmi Pharm. Co., Ltd. Long-acting conjugate of a physiologically active material and use thereof
CN106986924A (zh) * 2017-03-23 2017-07-28 中国药科大学 胃泌酸调节素（oxm）类似物及其应用
AR111341A1 (es) 2017-03-23 2019-07-03 Hanmi Pharm Ind Co Ltd Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo
KR101990075B1 (ko) * 2018-07-19 2019-06-18 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비만 예방 또는 치료용 약학 조성물
US12338270B2 (en) * 2018-07-19 2025-06-24 D&D Pharmatech Inc. Pharmaceutical composition comprising polypeptide
WO2020019813A1 (zh) * 2018-07-25 2020-01-30 中国药科大学 长效化胃泌酸调节素杂合肽及其制备方法和应用
CN113164559A (zh) * 2018-10-04 2021-07-23 韩美药品株式会社 胰高血糖素和包括胰高血糖素的组合产品的治疗用途
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
KR20210118857A (ko) * 2019-02-15 2021-10-01 한미정밀화학주식회사 생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법
CN111944055B (zh) * 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
JP2023525260A (ja) * 2020-05-09 2023-06-15 天津薬物研究院有限公司 二重受容体アゴニスト作用を有するポリペプチド誘導体及びその用途
KR20240053545A (ko) * 2022-10-14 2024-04-24 한미약품 주식회사 신규한 glp-1 수용체 길항제 및 이를 포함하는 선천성 고인슐린증 또는 저혈당증의 예방 또는 치료용 약학적 조성물

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
JP3895109B2 (ja) 1998-03-06 2007-03-22 中外製薬株式会社 蛋白非添加製剤
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7217845B2 (en) 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1594530A4 (en) * 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
RU2352583C2 (ru) 2003-11-13 2009-04-20 Ханми Фарм. Инд. Ко., Лтд. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US20090238838A1 (en) 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
CN101128487B (zh) 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
JP2008543816A (ja) * 2005-06-13 2008-12-04 インペリアル イノベーションズ リミテッド 新規化合物および該化合物が摂食行動に及ぼす効果
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
EP2471811B1 (en) 2006-02-22 2015-09-16 Merck Sharp & Dohme Corp. Oxyntomodulin derivatives
EP2046367A4 (en) 2006-06-07 2009-11-11 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
GB0624868D0 (en) 2006-12-13 2007-01-24 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
EP2175834B8 (en) 2007-07-10 2012-08-22 Eli Lilly And Company Glp-1-fc fusion protein formulation
RU2010113979A (ru) 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение bubuc и необязательно eaa-marti (26-35) в качестве терапевтического средства для лечения инфекций hcmv
ES2558155T3 (es) 2007-10-30 2016-02-02 Indiana University Research And Technology Corporation Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
CN101983066B (zh) 2008-01-30 2016-06-29 印第安那大学科技研究公司 基于酯的胰岛素前药
PA8830501A1 (es) 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
KR20110039230A (ko) 2008-06-17 2011-04-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체
WO2010013012A2 (en) 2008-08-01 2010-02-04 Lund University Bioscience Ab Novel polypeptides and uses thereof
US20110171312A1 (en) 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
US8642541B2 (en) 2008-12-15 2014-02-04 Zealand Pharma A/S Glucagon analogues
SG172291A1 (en) 2008-12-19 2011-07-28 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
WO2010096052A1 (en) * 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
CA2755336C (en) 2009-03-20 2015-07-14 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2010107256A2 (en) * 2009-03-20 2010-09-23 Hanmi Pharm. Co., Ltd. Method for preparing a site-specific physiologically active polypeptide conjugate
PE20120914A1 (es) 2009-06-16 2012-08-22 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip
DK2454282T3 (en) 2009-07-13 2015-05-04 Zealand Pharma As acetylated glucagonanaloger
US20120294855A1 (en) 2009-11-03 2012-11-22 Eli Lilly & Company Glp-1 receptor agonist compounds for obstructive sleep apnea
US20120269830A1 (en) 2009-12-07 2012-10-25 Lawrence Horowitz Conjugates with improved pharmacokinetic properties
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
CN102918055B (zh) 2010-03-26 2017-03-29 诺沃—诺迪斯克有限公司 新的胰高血糖素类似物
EP2568993A4 (en) 2010-05-13 2014-02-19 Univ Indiana Res & Tech Corp GLUCAGON SUPERFAMILY PEPTIDES WITH G-PROTEIN-COUPLED RECEPTOR ACTIVITY
WO2011163012A2 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
CN101974077A (zh) 2010-09-15 2011-02-16 南京瑞年天平医药科技有限公司 一种新颖的多肽化合物
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
KR101767570B1 (ko) 2010-10-26 2017-08-14 한미사이언스 주식회사 항 비만 펩타이드의 지속형 결합체
CN102010473A (zh) 2010-11-10 2011-04-13 曹鹏 重组胃泌酸调节素融合蛋白及其制备和应用
CN103402536A (zh) 2010-12-22 2013-11-20 马克迪亚生物科技公司 用gip和glp-1受体活性的基于胰高血糖素的肽来治疗代谢异常和肥胖的方法
EP2492749A1 (en) 2011-02-28 2012-08-29 Rohm and Haas Electronic Materials LLC Photoresist compositions and methods of forming photolithographic patterns
KR101161526B1 (ko) 2011-05-16 2012-07-02 숭실대학교산학협력단 연료전지용 촉매전극을 위한 코어/쉘 구조의 나노 지지체 및 그 제조방법
DK3878859T5 (da) 2011-06-10 2024-06-10 Hanmi Science Co Ltd Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende disse
SI2721062T1 (sl) 2011-06-17 2019-03-29 Hanmi Science Co., Ltd. Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega
JP6184404B2 (ja) 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン／ｇｌｐ−１レセプターコアゴニスト
BR112014025951A2 (pt) 2012-04-19 2017-07-11 Opko Biologics Ltd variantes de oxintomodulina de longa ação e métodos de produção do mesmo
ES2602486T3 (es) 2012-06-21 2017-02-21 Indiana University Research And Technology Corporation Análogos de glucagón que muestran actividad de receptor de GIP
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
MY168536A (en) 2012-11-06 2018-11-12 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin fc region
JP6137046B2 (ja) 2014-05-09 2017-05-31 信越化学工業株式会社 単量体、高分子化合物、レジスト材料及びパターン形成方法

Also Published As

Publication number Publication date
EP3878859A1 (en) 2021-09-15
US20170342122A1 (en) 2017-11-30
NZ740049A (en) 2019-05-31
JP2019189611A (ja) 2019-10-31
KR20120137271A (ko) 2012-12-20
AR086866A1 (es) 2014-01-29
BR112013031794A2 (pt) 2016-12-20
AU2018213964B2 (en) 2020-03-19
JP6312765B2 (ja) 2018-04-18
CA2838503A1 (en) 2012-12-13
RU2013154066A (ru) 2015-07-20
CY1120781T1 (el) 2019-12-11
SG10201604564XA (en) 2016-07-28
NZ731342A (en) 2017-09-29
EP3878859B1 (en) 2023-11-01
IL260582B (en) 2019-09-26
EP2718318B1 (en) 2018-07-25
BR112013031794B1 (pt) 2020-11-10
PE20240686A1 (es) 2024-04-10
AU2012267398A1 (en) 2014-01-16
UA114710C2 (uk) 2017-07-25
IL268984A (en) 2019-10-31
ZA201309054B (en) 2014-08-27
CA2838503C (en) 2020-02-18
JP2018117629A (ja) 2018-08-02
JP6862493B2 (ja) 2021-04-21
NZ734808A (en) 2018-11-30
PL2718318T3 (pl) 2019-02-28
RU2017105866A3 (es) 2020-06-26
AU2020201322B2 (en) 2021-04-29
ES2692187T3 (es) 2018-11-30
DK3878859T3 (da) 2024-01-02
WO2012169798A2 (en) 2012-12-13
US9527898B2 (en) 2016-12-27
CA3064214A1 (en) 2012-12-13
KR101573636B1 (ko) 2015-12-03
EP3434687A2 (en) 2019-01-30
DK2718318T3 (en) 2018-11-05
PT2718318T (pt) 2018-11-09
ES2875748T3 (es) 2021-11-11
JP6014127B2 (ja) 2016-10-25
EP2718318A4 (en) 2014-12-31
AU2016273908A1 (en) 2017-01-12
DK3878859T5 (da) 2024-06-10
RU2612906C2 (ru) 2017-03-13
US20150291679A1 (en) 2015-10-15
WO2012169798A3 (en) 2013-02-14
IL245557A0 (en) 2016-06-30
IL245557B (en) 2018-12-31
AU2020201322A1 (en) 2020-03-12
US10442848B2 (en) 2019-10-15
NZ618810A (en) 2016-03-31
KR101502299B1 (ko) 2015-03-11
HRP20181591T1 (hr) 2018-11-30
NZ717174A (en) 2017-07-28
HUE040307T2 (hu) 2019-02-28
MX350708B (es) 2017-09-14
PE20140765A1 (es) 2014-06-14
RU2739209C2 (ru) 2020-12-21
US20170022261A1 (en) 2017-01-26
TWI619724B (zh) 2018-04-01
PH12013502518A1 (en) 2014-01-20
EP2718318A2 (en) 2014-04-16
BR122020011001B1 (pt) 2022-09-20
SMT201800649T1 (it) 2019-01-11
CN103732618B (zh) 2018-10-09
AU2012267398B2 (en) 2016-10-13
US20140128318A1 (en) 2014-05-08
TW201803895A (zh) 2018-02-01
JP2014516566A (ja) 2014-07-17
IL268984B (en) 2021-04-29
RS57711B1 (sr) 2018-12-31
JP2017043624A (ja) 2017-03-02
TW201307380A (zh) 2013-02-16
JP2020183433A (ja) 2020-11-12
DK3434687T3 (da) 2021-06-07
MX2022004041A (es) 2022-08-10
NZ748012A (en) 2020-01-31
PH12018501954A1 (en) 2023-02-13
AU2018213964A1 (en) 2018-08-23
KR20140130659A (ko) 2014-11-11
CL2013003547A1 (es) 2014-06-27
CA3064214C (en) 2023-03-07
CN103732618A (zh) 2014-04-16
US9765131B2 (en) 2017-09-19
US9522946B2 (en) 2016-12-20
MX2013014468A (es) 2014-05-13
UA126465C2 (uk) 2022-10-12
ES2968043T3 (es) 2024-05-06
RU2017105866A (ru) 2019-01-23
SI2718318T1 (sl) 2018-11-30
MY169309A (en) 2019-03-21
JP7094327B2 (ja) 2022-07-01
LT2718318T (lt) 2018-10-25
SG195258A1 (en) 2013-12-30
EP3434687A3 (en) 2019-02-20
EP3434687B1 (en) 2021-03-10
MX391293B (es) 2025-03-21
TWI674271B (zh) 2019-10-11
AU2016273908B2 (en) 2018-08-23
NZ755534A (en) 2020-10-30

Similar Documents

Publication Publication Date Title
PE20181299A1 (es) Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos
AR086969A1 (es) Conjugado que comprende oxontomodulina y un fragmento de inmunoglobulina, y su uso
PE20190355A1 (es) Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo
AR105485A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
PE20171154A1 (es) Derivados de glucagon con estabilidad mejorada
JP2018504901A5 (es)
CL2020002010A1 (es) Uso de un polipéptido que comprende una hormona de crecimiento, y ctps adheridos a la misma, para inducir crecimiento o ganancia de peso. (divisional solicitud 201400254)
CL2012001685A1 (es) Análogo peptídico de oxintomodulina, en donde el aminoácido c-terminal es opcionalmente amidado; composición farmacéutica que lo comprende; y su uso en la preparación de un medicamento para el tratamiento de diabetes no insulinodependiente u obesidad.
CL2012001686A1 (es) Analogo peptidico de oxintomodulina, en donde el aminoacido c-terminal es opcionalmente amidado; composicion farmaceutica que lo comprende y su uso en la preparacion de un medicamento para el tratamiento de diabetes no insulinodependiente u obesidad.
PE20180158A1 (es) Coagonistas de los receptores de glucagon y de glp-1
IL262805B2 (en) Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
AR093903A1 (es) Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad
AR110887A2 (es) Región constante de anticuerpo mutante
CA2790380A1 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
MX2020010806A (es) Peptidos anti-inflamatorios y usos de los mismos.
PE20211466A1 (es) Analogos de proteina tirosina-tirosina y metodos de uso de esta
PE20120563A1 (es) Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
CL2012000119A1 (es) Polipeptido f de virus respiratorio sincicial recombinante, composicion inmunogenica que lo comprende, uso para la preparacion de un medicamento para la profilaxis contra dicho virus.
NZ579566A (en) Modified fgf-21 polypeptides and their uses
EA201100038A1 (ru) Коагонисты глюкагонового рецептора/glp-1-рецептора
ES2673556T3 (es) Vacunas para el VHS-2
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
EA201291234A1 (ru) Аналоги глюкагона
RU2014133818A (ru) Стабилизированный состав pth
MX2016001971A (es) Composiciones farmaceuticas parenterales acuosas estables de peptidos insulinotropicos.